Protara Therapeutics (NASDAQ:TARA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a report issued on Monday, Benzinga reports. HC Wainwright currently has a $23.00 price target on the stock.

Separately, Oppenheimer boosted their price target on shares of Protara Therapeutics from $26.00 to $30.00 and gave the company an outperform rating in a research report on Monday, April 22nd.

Protara Therapeutics Stock Performance

TARA opened at $2.83 on Monday. The business’s 50-day simple moving average is $3.53 and its 200-day simple moving average is $2.57. The company has a market cap of $32.35 million, a P/E ratio of -0.76 and a beta of 1.80. Protara Therapeutics has a one year low of $1.04 and a one year high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.13. As a group, analysts predict that Protara Therapeutics will post -3.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Protara Therapeutics

An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned 0.09% of Protara Therapeutics as of its most recent SEC filing. 38.13% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.